Stock Analiz

ImageneBio, Inc. IMA

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$3.47Market cap $43M
Open the interactive analysis →

ImageneBio, Inc. (IMA) is a healthcare company listed in the US with a market value of about $43M. In fiscal year 2025 it had revenue of $800000 and net income of -$45M, a net margin of -5668.6%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -39% a year, a 5-year average ROIC of -31%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About ImageneBio

ImageneBio is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $9M in 2020 to $800000 in 2025, a decline of about 38.6% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 444% over three years (dilution for shareholders). It spends 3566% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S54.0
P/B0.3
EV/EBITDA—
PEG—
Dividend yield—
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)-77.1%
Revenue growth (5 yrs, per year)-38.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1601.6%
ROIC (5-yr avg.)-31.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal year202520242023202220212020
Revenue$800000$4M$9M$16M$31M$9M
Net income-$45M-$37M-$68M-$69M-$34M-$44M
Free cash flow——-$80M-$76M-$62M-$39M
EPS (diluted)$-9.64$-22.10$-65.87$-76.78$-49.30$-646.58
Net margin-5668.6%-1044.8%-744.2%-440.3%-110.1%-481.4%
ROIC-35.3%——-46.4%-12.6%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is ImageneBio stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does ImageneBio pay a dividend?

Not currently.

Is ImageneBio a good stock to buy?

We do not give buy or sell advice. ImageneBio scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.